Valuation: GlaxoSmithKline plc

Market Cap 7.98TCr 11TCr 9.34TCr 8.61TCr 15TCr 10,13300Cr 15TCr 1,03300Cr 40TCr 5,00100Cr 40TCr 39TCr 17,28600Cr P/E 2026 *
12.7x
P/E 2027 * 11.7x
Enterprise Value 9.52TCr 13TCr 11TCr 10TCr 18TCr 12,09300Cr 18TCr 1,23200Cr 48TCr 5,96800Cr 48TCr 47TCr 20,62800Cr EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.59x
Free-Float
92.29%
Yield 2026 *
3.51%
Yield 2027 * 3.7%
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%+2.81%+59.55%+172.77% 1,07000Cr
+2.87%+4.96%+71.68%+67.39% 62TCr
-0.02%+1.23%+35.76%+88.00% 45TCr
+2.14%-2.07%+27.62%+22.57% 33TCr
+1.87%+1.87%+40.58%+42.08% 29TCr
+1.36%+0.17%+29.90%+49.33% 28TCr
+1.98%+4.08%-25.78%-39.02% 22TCr
+0.14%+1.39%+25.33%+67.92% 20TCr
+4.26%+6.83%+20.75%+81.36% 16TCr
Average +1.95%+0.98%+31.71%+61.38% 40.27TCr
Weighted average by Cap. +2.08%+0.70%+43.24%+87.83%

Financials

2026 *2027 *
Net sales 3.39TCr 4.53TCr 3.96TCr 3.65TCr 6.43TCr 4,30000Cr 6.53TCr 44TCr 17TCr 2,12200Cr 17TCr 17TCr 7,33400Cr 3.56TCr 4.76TCr 4.17TCr 3.84TCr 6.76TCr 4,51900Cr 6.87TCr 46TCr 18TCr 2,23000Cr 18TCr 17TCr 7,70800Cr
Net income 647.33Cr 865.97Cr 757.81Cr 698.39Cr 1.23TCr 82TCr 1.25TCr 8.37TCr 3.26TCr 41TCr 3.25TCr 3.18TCr 1,40200Cr 693.86Cr 928.21Cr 812.28Cr 748.59Cr 1.32TCr 88TCr 1.34TCr 8.98TCr 3.49TCr 43TCr 3.48TCr 3.41TCr 1,50300Cr
Net Debt 1.54TCr 2.06TCr 1.81TCr 1.66TCr 2.93TCr 1,95900Cr 2.98TCr 20TCr 7.76TCr 97TCr 7.75TCr 7.58TCr 3,34200Cr 1.22TCr 1.64TCr 1.43TCr 1.32TCr 2.32TCr 1,55400Cr 2.36TCr 16TCr 6.16TCr 77TCr 6.15TCr 6.01TCr 2,65000Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-